

● 文献

- 1) Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. *J Lab Clin Med.* 1955 ; 45 (1) : 3-17.
- 2) Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. *Hypertension.* 2013 ; 62 (2) : 331-336.
- 3) Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, Kurihara I, Itoh H, Umakoshi H, Tsuiki M, Ichijo T, Katabami T, Tanaka Y, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Okamura S, Miyauchi S, Fukuoka T, Izawa S, Yoneda T, Hashimoto S, Yanase T, Suzuki T, Kawamura T, Tabara Y, Matsuda F, Naruse M; Nagahama Study; JPAS Study Group. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. *Hypertension.* 2018 ; 71 (3) : 530-537.
- 4) Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol.* 2018 ; 6 (1) : 41-50.
- 5) Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshida S, Ikeda S, Ishimitsu T, Ito M, Ito S, Iwashima Y, Kai H, Kamide K, Kanno Y, Kashihara N, Kawano Y, Kikuchi T, Kitamura K, Kitazono T, Kohara K, Kudo M, Kumagai H, Matsumura K, Matsuura H, Miura K, Mukoyama M, Nakamura S, Ohkubo T, Ohya Y, Okura T, Rakugi H, Saitoh S, Shibata H, Shimosawa T, Suzuki H, Takahashi S, Tamura K, Tomiyama H, Tsuchihashi T, Ueda S, Uehara Y, Urata H, Hirawa N. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). *Hypertens Res.* 2019 ; 42 (9) : 1235-1481.
- 6) 日本内分泌学会「原発性アルドステロン症ガイドライン実施の実態調査と普及に向けた標準化に関する検討」委員会 編集. わが国の原発性アルドステロン症の診療に関するコンセンサス・ステートメント. 診断と治療社. 2016
- 7) Käyser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, Hermus AR, Lenders JW, Deinum J. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. *J Clin Endocrinol Metab.* 2016 ; 101 (7) : 2826-2835.
- 8) Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient's cohorts and in population-based studies--a review of the current literature. *Horm Metab Res.* 2012 ; 44 (3) : 157-162.
- 9) Burrello J, Monticone S, Losano I, Cavaglià G, Buffolo F, Tetti M, Covella M, Rabbia F, Veglio F, Pasini B, Williams TA, Mulatero P. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. *Hypertension.* 2020 ; 75 (4) : 1025-1033.
- 10) Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A; Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatments of primary aldosteronism-the Japan Endocrine Society 2009. *Endocr J.* 2011 ; 58 (9) : 711-721.
- 11) Fujii Y, Takeda Y, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Yamamoto K, Ogo A, Yanase T, Okamura S, Miyauchi S, Fujita M, Suzuki T, Umakoshi H, Ogasawara T, Tsuiki M, Naruse M; JPAS Study Group. Historical changes and between-facility differences in adrenal venous sampling for primary aldosteronism in Japan. *J Hum Hypertens.* 2020 (1) : 34 : 34-42.
- 12) Ohno Y, Naruse M, Beuschlein F, Schreiner F, Parasiliti-Caprino M, Deinum J, Drake WM, Fallo F, Fuss CT, Grytaas MA, Ichijo T, Inagaki N, Kakutani M, Kastelan D, Kraljevic I, Katabami T, Kocjan T, Monticone S, Mulatero P, O'Toole S, Kobayashi H, Sone M, Tsuiki M, Wada N, Williams TA, Reincke M, Tanabe A. Adrenal venous sampling guided adrenalectomy rates in primary aldosteronism: results of an international cohort (AVSTAT). *J Clin Endocrinol Metab.* 2021 ; 106 (3) : e1400-e1407
- 13) Kawashima A, Sone M, Inagaki N, Takeda Y, Itoh H, Kurihara I, Umakoshi H, Ichijo T, Katabami T, Wada N, Ogawa Y, Kawashima J, Fujita M, Miyauchi S, Okamura S, Fukuoka T, Yanase T, Izawa S, Yoshikawa Y, Hashimoto S, Yamada M, Kai T, Suzuki T, Naruse M. Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism. *Eur J Endocrinol.* 2019 ; 181 (3) : 339-350.
- 14) Ohno Y, Sone M, Inagaki N, Kawashima A, Takeda Y, Yoneda T, Kurihara I, Itoh H, Tsuiki M, Ichijo T, Katabami T, Wada N, Sakamoto R, Ogawa Y, Yoshimoto T, Yamada T, Kawashima J, Matsuda Y, Kobayashi H, Kamemura K, Yamamoto K, Otsuki M, Okamura S, Izawa S, Okamoto R, Tamura K, Tanabe A, Naruse M; JPAS/JRAS Study Group. Nadir aldosterone levels after confirmatory tests are correlated with left ventricular hypertrophy in primary aldosteronism. *Hypertension.* 2020 ; 75 (6) : 1475-1482.
- 15) Murata M, Kitamura T, Tamada D, Mukai K, Kurebayashi S, Yamamoto T, Hashimoto K, Hayashi RD, Kouhara H, Takeiri S, Kajimoto Y, Nakao M, Hamasaki T, Otsuki M, Shimomura I. Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. *J Hypertens.* 2017 ; 35 (5) : 1079-1085
- 16) Tang L, Li X, Wang B, Ma X, Li H, Gao Y, Gu L, Nie W, Zhang X. Clinical characteristics of aldosterone- and cortisol-coproducing adrenal adenoma in primary aldosteronism. *Int J Endocrinol.* 2018 ; 2018 : 4920841.
- 17) Monticone S, Sconfienza E, D'Ascenzo F, Buffolo F, Satoh F, Sechi LA, Veglio F, Mulatero P. Renal damage in primary aldosteronism: a systematic review and meta-analysis. *J Human Hypertension.* 2020 ; 38 (1) : 3-12
- 18) Iwakura Y, Morimoto R, Kudo M, Ono Y, Takase K, Seiji K, Arai Y, Nakamura Y, Sasano H, Ito S, Satoh F. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal

- outcome of 213 cases. *J Clin Endocrinol Metab.* 2014 ; 99 (5) : 1593-1598.
- 19) Kobayashi H, Abe M, Nakamura Y, Takahashi K, Fujita M, Takeda Y, Yoneda T, Kurihara I, Itoh H, Tsuiki M, Wada N, Ichijo T, Katabami T, Ogawa Y, Kawashima J, Yoshimoto T, Sone M, Inagaki N, Watanabe M, Kamemura K, Matsuda Y, Izawa S, Tanabe M, Tanabe A, Suzuki T, Naruse M; JPAS/JRAS Study Group. Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function. *Hypertension.* 2019 ; 74 (3) : 630-638.
 - 20) Akehi Y, Yanase T, Motonaga R, Umakoshi H, Tsuiki M, Takeda Y, Yoneda T, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ashida K, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Okamura S, Miyauchi S, Fukuo-ka T, Izawa S, Hashimoto S, Yamada M, Yoshikawa Y, Kai T, Suzuki T, Kawamura T, Naruse M; Japan Primary Aldosteronism Study Group. High prevalence of diabetes in patients with primary aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA: a large, multicenter cohort study in Japan. *Diabetes Care.* 2019 ; 42 (5) : 938-945.
 - 21) Buffolo F, Li Q, Monticone S, Heinrich DA, Mattei A, Pieroni J, Mei M, Yang S, Hu YH, Yang MC, Sabbadin C, Pizzolo F, Giacchetti G, Fallo F, Veglio F, Reincke M, Wu VC, Mulatero P. Primary aldosteronism and obstructive sleep apnea: a cross-sectional multi-ethnic study. *Hypertension.* 2019 ; 74 (6) : 1532-1540.
 - 22) Heinrich DA, Adolf C, Rump LC, Quack I, Quinkler M, Hahner S, Januszewicz A, Seufert J, Willenberg HS, Nirschl N, Sturm L, Beuschlein F, Reincke M. Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms. *Eur J Endocrinol.* 2018 ; 178 (6) : 605-611.
 - 23) Lubitz CC, Economopoulos KP, Sy S, Johanson C, Kunzel HE, Reincke M, Gazelle GS, Weinstein MC, Gaziano TA. Cost-effectiveness of screening for primary aldosteronism and subtype diagnosis in the resistant hypertensive patients. *Circ Cardiovasc Qual Outcomes.* 2015 ; 8 (6) : 621-630.
 - 24) Sato M, Morimoto R, Seiji K, Iwakura Y, Ono Y, Kudo M, Satoh F, Ito S, Ishibashi T, Takase K. Cost-effectiveness analysis of the diagnosis and treatment of primary aldosteronism in Japan. *Horm Metab Res.* 2015 ; 47 (11) : 826-32.
 - 25) Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2016 ; 101 (5) : 1889-1916.
 - 26) Hannemann A, Bidlingmaier M, Friedrich N, Manolopoulou J, Spyroglou A, Völzke H, Beuschlein F, Scissler J, Rettig R, Felix SB, Biffar R, Döring A, Meisinger C, Peters A, Wichmann HE, Nauck M, Wallaschofski H, Reincke M. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. *Eur J Endocrinol.* 2012 ; 167 (1) : 7-15.
 - 27) Miyaji Y, Kawabata Y, Joki H, Seki S, Mori K, Kamide T, Tamase A, Shima H, Nomura M, Kitamura Y, Nakaguchi H, Minami T, Tsunoda T, Sasaki M, Yamada M, Tanaka F. Primary aldosteronism in patients with acute stroke: prevalence and diagnosis during initial hospitalization. *BMC Neurol.* 2016 ; 16 : 177.
 - 28) Sim JJ, Yan EH, Liu IL, Rasgon SA, Kalantar-Zadeh K, Calhoun DA, Derose SF. Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. *J Hypertens.* 2011 ; 29 (8) : 1553-1559.
 - 29) Aglony M, Martínez-Aguayo A, Carvajal CA, Campino C, García H, Bancalari R, Bolte L, Avalos C, Loureiro C, Trejo P, Brinkmann K, Giadrosich V, Mericq V, Rocha A, Avila A, Perez V, Inostroza A, Fardella CE. Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population: clinical and biochemical presentation. *Hypertension.* 2011 ; 57 (6) : 1117-1121.
 - 30) Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, Schiavone D, Williams TA, Einaudi S, La Grotta A, Rabbia F, Veglio F. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TORino-GENetic forms) *Hypertension.* 2011 ; 58 (5) : 797-803.
 - 31) Morimoto R, Ono Y, Tezuka Y, Kudo M, Yamamoto S, Arai T, Gomez-Sanchez CE, Sasano H, Ito S, Satoh F. Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay. *Hypertension.* 2017 ; 70 (2) : 334-341.
 - 32) Teruyama K, Naruse M, Tsuiki M, Kobayashi H. Novel chemiluminescent immunoassay to measure plasma aldosterone and plasma active renin concentrations for the diagnosis of primary aldosteronism. *J Human Hypertens.* 2021 <https://doi.org/10.1038/s41371-020-00465-5>
 - 33) Young WF. Primary aldosteronism: renaissance of a syndrome. *Clin Endocrinol (Oxf)* . 2007 ; 66 (5) : 607-618.
 - 34) Kaplan NM. Primary aldosteronism: evidence against a second epidemic. *J Hypertens.* 2021 ; 30 (10) : 1899-1902.
 - 35) Ducher M, Mounier-Véhier C, Bague JP, Tartière JM, Sosner P, Régnier-Le Coz S, Perez L, Fourcade J, Jabourec O, Lejeune S, Stolz A, Fauvel JP. Aldosterone-to-renin ratio for diagnosing aldosterone-producing adenoma: a multicentre study. *Arch Cardiovasc Dis.* 2012 ; 105 (12) : 623-630.
 - 36) Unger N, Lopez Schmidt I, Pitt C, Walz MK, Philipp T, Mann K, Petersenn S. Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass. *Eur J Endocrinol.* 2004 ; 150 (4) : 517-523.
 - 37) Leung AA, Orton DJ, Chin A, Sadrzadeh H, Kline GA. Novel Approach to Establishing an Aldosterone: Renin Ratio Cutoff for Primary Aldosteronism. *Hypertension.* 2017 ; 69 (3) : 450-456.
 - 38) Burrello J, Monticone S, Buffolo F, Lucchiari M, Tetti M, Rabbia F, Mengozzi G, Williams TA, Veglio F, Mulatero P. Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. *J Hypertens.* 2016 ; 34 (5) : 920-927.
 - 39) Yin G, Zhang S, Yan L, Wu M, Xu M, Li F, Cheng H. Effect of age on aldosterone/renin ratio (ARR) and comparison of

- screening accuracy of ARR plus elevated serum aldosterone concentration for primary aldosteronism screening in different age groups. *Endocrine*. 2012 ; 42 (1) : 182-189.
- 40) Luo Q, Li NF, Yao XG, Zhang DL, Abulikemu SF, Chang GJ, Zhou KM, Wang GL, Wang MH, Ouyang WJ, Cheng QY, Jia Y. Potential effects of age on screening for primary aldosteronism. *J Hum Hypertens*. 2016 ; 30 (1) : 53-61.
 - 41) 日本内分泌学会「血中アルドステロン測定 of 標準化検討」委員会 編集. 血中アルドステロン測定 of 互換性確認試験報告書. 2020.
 - 42) Nishikawa T, Omura M, Kawaguchi M, Takatsu A, Satoh F, Ito S, Kurihara I, Itoh H, Yanase T, Shibata H, Oki Y, Naruse M, Sakurai K, Sasamoto H, Kuwa K. Calibration and evaluation of routine methods by serum certified reference material for aldosterone measurement in blood. *Endocr J*. 2016 ; 63 (12) : 1065-1080.
 - 43) Ozeki Y, Tanimura Y, Nagai S, Nomura T, Kinoshita M, Shibata K, Matsuda N, Miyamoto S, Yoshida Y, Okamoto M, Gotoh K, Masaki T, Kambara K, and Shibata H. Development of a new chemiluminescent enzyme immunoassay using a two-step-sandwich method for measuring aldosterone concentrations. *Diagnostics (Basel)*. 2021 ; 11 (3) : 433.
 - 44) Thuzar M, Young K, Ahmed AH, Ward G, Wolley M, Guo Z, Gordon RD, McWhinney BC, Ungerer JP, Stowasser M. Diagnosis of primary aldosteronism by seated saline suppression test-variability between immunoassay and HPLC-MS/MS. *J Clin Endocrinol Metab*. 2020 ; 105 (3) : dgz150.
 - 45) Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, Kong AP. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. *J Clin Endocrinol Metab*. 2005 ; 90 (1) : 72-78.
 - 46) Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. *Hypertension*. 2002 ; 40 (6) : 897-902.
 - 47) Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. *Clin Endocrinol (Oxf)*. 2002 ; 57 (4) : 457-465.
 - 48) Murase K, Nagaishi R, Takenoshita H, Nomiya T, Akehi Y, Yanase T. Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension. *Endocr J*. 2013 ; 60 (8) : 967-976.
 - 49) Nagasawa M, Yamamoto K, Rakugi H, Takeda M, Akasaka H, Umakoshi H, Tsuiki M, Takeda Y, Kurihara I, Itoh H, Ichijo T, Katabami T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Ogo A, Okamura S, Miyauchi S, Yanase T, Suzuki T, Kawamura T, Naruse M; JPAS Study Group. Influence of antihypertensive drugs in the subtype diagnosis of primary aldosteronism by adrenal venous sampling. *J Hypertens*. 2019 ; 37 (7) : 1493-1499.
 - 50) 西川哲男, 桑 克彦. アルドステロン測定 of 標準化 of 現状. *糖尿病・内分泌代謝科*, 2021 ; 52 (2) : 496-503.
 - 51) Morera J, Reznik Y. Management of endocrine disease: The role of confirmatory tests in the diagnosis of primary aldosteronism. *Eur J Endocrinol*. 2019 ; 180 (2) : R45-R58.
 - 52) Saiki A, Tamada D, Hayashi R, Mukai K, Kitamura T, Takahara M, Otsuki M, Shimomura I. The number of positive confirmatory tests is associated with the clinical presentation and incidence of cardiovascular and cerebrovascular events in primary aldosteronism. *Hypertens Res*. 2019 ; 42 (8) : 1186-1191.
 - 53) Wu S, Yang J, Hu J, Song Y, He W, Yang S, Luo R, Li Q. Confirmatory tests for the diagnosis of primary aldosteronism: a systematic review and meta-analysis. *Clin Endocrinol (Oxf)*. 2019 ; 90 (5) : 641-648.
 - 54) Wu J, Tian W, Zhang L, Zhang J, Zhou B. Assessing the quality of guidelines for primary aldosteronism: which guidelines are worth applying in diverse settings? *J Hypertens*. 2019 ; 37 (7) : 1500-1512.
 - 55) Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F; Primary Aldosteronism Prevalence in Italy Study Investigators. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. *Hypertension*. 2007 ; 50 (2) : 424-431.
 - 56) Song Y, Yang S, He W, Hu J, Cheng Q, Wang Y, Luo T, Ma L, Zhen Q, Zhang S, Mei M, Wang Z, Qing H, Bruemmer D, Peng B, Li Q; Chongqing Primary Aldosteronism Study (CONPASS) Group. Confirmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study. *Hypertension*. 2018 ; 71 (1) : 118-124.
 - 57) Kidoguchi S, Sugano N, Hayashi-Ishikawa N, Morisawa N, Tokudome G, Yokoo T. The characteristics of captopril challenge test-positive patients using various criteria. *J Renin Angiotensin Aldosterone Syst*. 2019 ; 20 (3) : 1470320319870891
 - 58) Stowasser M, Ahmed AH, Cowley D, Wolley M, Guo Z, McWhinney BC, Ungerer JP, Gordon RD. Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism. *J Clin Endocrinol Metab*. 2018 ; 103 (11) : 4113-4124.
 - 59) Ceral J, Malirova E, Ballon M, Solar M. The role of urinary aldosterone for the diagnosis of primary aldosteronism. *Horm Metab Res*. 2014 ; 46 (9) : 663-667.
 - 60) Reznik Y, Amar L, Tabarin A. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: confirmatory testing. *Ann Endocrinol (Paris)*. 2016 ; 77 (3) : 202-207.
 - 61) Vivien M, Deberles E, Morello R, Haddouche A, Guenet D, Reznik Y. Evaluation of biochemical conditions allowing bypass of confirmatory testing in the workup of primary aldosteronism: a retrospective study in a French hypertensive population. *Horm Metab Res*. 2019 ; 51 (3) : 172-177.
 - 62) Kawashima J, Araki E, Naruse M, Kurihara I, Takahashi K, Tamura K, Kobayashi H, Okamura S, Miyauchi S, Yamamoto K, Izawa S, Suzuki T, Tanabe A. Baseline plasma aldosterone level and renin activity allowing omission of confirmatory testing in primary aldosteronism. *J Clin Endocrinol Metab*. 2020 ; 105 (5) : dgaa117.

- 63) Umakoshi H, Sakamoto R, Matsuda Y, Yokomoto-Umakoshi M, Nagata H, Fukumoto T, Ogata M, Ogawa Y. Role of aldosterone and potassium levels in sparing confirmatory tests in primary aldosteronism. *J Clin Endocrinol Metab.* 2020 ; 105 (4) : dgz148.
- 64) Wang K, Hu J, Yang J, Song Y, Fuller PJ, Hashimura H, He W, Feng Z, Cheng Q, Du Z, Wang Z, Ma L, Yang S, Li Q. Development and validation of criteria for sparing confirmatory tests in diagnosing primary aldosteronism. *J Clin Endocrinol Metab* 2020 ; 105 (7) : dga282.
- 65) Gerards J, Heinrich DA, Adolf C, Meisinger C, Rathmann W, Sturm L, Nirschl N, Bidlingmaier M, Beuschlein F, Thorand B, Peters A, Reincke M, Roden M, Quinkler M. Impaired glucose metabolism in primary aldosteronism is associated with cortisol cosecretion. *J Clin Endocrinol Metab.* 2019 ; 104 (8) : 3192-3202.
- 66) Inoue K, Yamazaki Y, Tsurutani Y, Suematsu S, Sugisawa C, Saito J, Omura M, Sasano H, Nishikawa T. Evaluation of cortisol production in aldosterone-producing adenoma. *Horm Metab Res.* 2017 ; 49 (11) : 847-853.
- 67) Hiraishi K, Yoshimoto T, Tsuchiya K, Minami I, Doi M, Izumiya H, Sasano H, Hirata Y. Clinicopathological features of primary aldosteronism associated with subclinical Cushing's syndrome. *Endocr J.* 201 ; 58 (7) : 543-551.
- 68) Späth M, Korovkin S, Antke C, Anlauf M, Willenberg HS. Aldosterone- and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism. *Eur J Endocrinol.* 2011 ; 164 (4) : 447-455.
- 69) Nakajima Y, Yamada M, Taguchi R, Satoh T, Hashimoto K, Ozawa A, Shibusawa N, Okada S, Monden T, Mori M. Cardiovascular complications of patients with aldosteronism associated with autonomous cortisol secretion. *J Clin Endocrinol Metab.* 2011 ; 96 (8) : 2512-2518.
- 70) Ohno Y, Sone M, Inagaki N, Takeda Y, Kurihara I, Tsuiki M, Ichijo T, Wada N, Katabami T, Ogawa Y, Okamura S, Fukuoka T, Kai T, Izawa S, Yoshikawa Y, Hashimoto S, Yamada M, Chiba Y, Naruse M; JPAS/JRAS Study Group. Latent autonomous cortisol secretion from apparently nonfunctioning adrenal tumor in nonlateralized hyperaldosteronism. *J Clin Endocrinol Metab.* 2019 ; 104 (10) : 4382-4389.
- 71) Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, Satoh F, Young WF Jr. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. *Hypertension.* 2014 ; 63 (1) : 151-160.
- 72) Yanase T, Oki Y, Katabami T, Otsuki M, Kageyama K, Tanaka T, Kawate H, Tanabe M, Doi M, Akehi Y, Ichijo T. New diagnostic criteria of adrenal subclinical Cushing's syndrome: opinion from the Japan Endocrine Society. *Endocr J.* 2018 ; 65 (4) : 383-393.
- 73) Katabami T, Fukuda H, Tsukiyama H, Tanaka Y, Takeda Y, Kurihara I, Ito H, Tsuiki M, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Yanase T, Suzuki T, Naruse M; JPAS/JRAS Study Group. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism. *J Hypertens.* 2019 ; 37 (7) : 1513-1520.
- 74) Chen YY, Lin YH, Huang WC, Chueh E, Chen L, Yang SY, Lin PC, Lin LY, Lin YH, Wu VC, Chu TS, Wu KD. Adrenalectomy improves the long-term risk of end-stage renal disease and mortality of primary aldosteronism. *J Endocr Soc.* 2019 ; 3 (6) : 1110-1126.
- 75) Kamemura K, Wada N, Ichijo T, Matsuda Y, Fujii Y, Kai T, Fukuoka T, Sakamoto R, Ogo A, Suzuki T, Umakoshi H, Tsuiki M, Naruse M. Significance of adrenal computed tomography in predicting laterality and indicating adrenal vein sampling in primary aldosteronism. *J Hum Hypertens.* 2017 ; 31 (3) : 195-199.
- 76) Umakoshi H, Tsuiki M, Takeda Y, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Yanase T, Suzuki T, Naruse M; JPAS Study Group. Significance of computed tomography and serum potassium in predicting subtype diagnosis of primary aldosteronism. *J Clin Endocrinol Metab.* 2018 ; 103 (3) : 900-908.
- 77) Ladurner R, Sommerey S, Buechner S, Dietz A, Degenhart C, Hallfeldt K, Gallwas J. Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism. *Eur J Clin Invest.* 2017 ; 47 (5) : 372-377.
- 78) Kempers MJ, Lenders JW, van Outhousden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, Deinum J. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. *Ann Intern Med.* 2009 ; 151 (5) : 329-337.
- 79) Umakoshi H, Ogasawara T, Takeda Y, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Yanase T, Okamura S, Miyauchi S, Suzuki T, Tsuiki M, Naruse M. Accuracy of adrenal computed tomography in predicting the unilateral subtype in young patients with hypokalaemia and elevation of aldosterone in primary aldosteronism. *Clin Endocrinol (Oxf).* 2018 ; 88 (5) : 645-651.
- 80) Williams TA, Burrello J, Sechi LA, Fardella CE, Matrozoza J, Adolf C, Baudrand R, Bernardi S, Beuschlein F, Catena C, Doumas M, Fallo F, Giacchetti G, Heinrich DA, Saint-Hilary G, Jansen PM, Januszewicz A, Kocjan T, Nishikawa T, Quinkler M, Satoh F, Umakoshi H, Widimský J Jr, Hahner S, Douma S, Stowasser M, Mulatero P, Reincke M. Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism. *Hypertension.* 2018 ; 72 (3) : 641-649.
- 81) Kobayashi H, Abe M, Soma M, Takeda Y, Kurihara I, Itoh H, Umakoshi H, Tsuiki M, Katabami T, Ichijo T, Wada N, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Shibata H, Kamemura K, Yanase T, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Nanba K, Tanabe A, Suzuki T, Naruse M; JPAS Study Group. Development and validation of subtype prediction scores for the workup of primary aldosteronism. *J Hypertens.* 2018 ; 36 (11) : 2269-2276.
- 82) Lingam RK, Sohaib SA, Rockall AG, Isidori AM, Chew S, Monson JP, Grossman A, Besser GM, Reznick RH. Diagnostic performance of CT versus MR in detecting aldosterone-producing adenoma in primary hyperaldosteronism (Conn's syndrome).

- Eur Radiol. 2004 ; 14 (10) : 1787-1792.
- 83) Raman SP, Lessne M, Kawamoto S, Chen Y, Salvatori R, Prescott JD, Fishman EK. Diagnostic performance of multidetector computed tomography in distinguishing unilateral from bilateral abnormalities in primary hyperaldosteronism: comparison of multidetector computed tomography with adrenal vein sampling. *J Comput Assist Tomogr.* 2015 ; 39 (3) : 414-418.
- 84) Ota H, Seiji K, Kawabata M, Satani N, Omata K, Ono Y, Iwakura Y, Morimoto R, Matsuura T, Kudo M, Tominaga J, Satoh F, Ito S, Takase K. Dynamic multidetector CT and non-contrast-enhanced MR for right adrenal vein imaging: comparison with catheter venography in adrenal venous sampling. *Eur Radiol.* 2016 ; 26 (3) : 622-630.
- 85) Morita S, Nishina Y, Yamazaki H, Sonoyama Y, Ichihara A, Sakai S. Dual adrenal venous phase contrast-enhanced MDCT for visualization of right adrenal veins in patients with primary aldosteronism. *Eur Radiol.* 2016 ; 26 (7) : 2073-2077.
- 86) Japanese Society of Nephrology. Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018. *Clin Exp Nephrol.* 2019 23 (1) : 1-15.
- 87) Isaka Y, Hayashi H, Aonuma K, Horio M, Terada Y, Doi K, Fujigaki Y, Yasuda H, Sato T, Fujikura T, Kuwatsuru R, Toei H, Murakami R, Saito Y, Hirayama A, Murohara T, Sato A, Ishii H, Takayama T, Watanabe M, Awai K, Oda S, Murakami T, Yagyū Y, Joki N, Komatsu Y, Miyauchi T, Ito Y, Miyazawa R, Kanno Y, Ogawa T, Hayashi H, Koshi E, Kosugi T, Yasuda Y; Japanese Society of Nephrology, Japan Radiological Society, and Japanese Circulation Society Joint Working Group. Guideline on the use of iodinated contrast media in patients with kidney disease 2018. *Clin Exp Nephrol.* 2020 ; 24 (1) : 1-44.
- 88) ACR Committee on Drugs and Contrast Media. ACR Manual on Contrast Media 2020. American College of Radiology. 2020. <https://www.acr.org/Clinical-Resources/Contrast-Manual>.
- 89) 日本医学放射学会造影剤安全管理委員会. ヨード造影剤ならびにガドリニウム造影剤の急性副作用発症の危険性低減を目的としたステロイド前投薬に関する提言 (2018年11月改訂版) 日本医学放射線学会. 2018. http://www.radiology.jp/member_info/safty/20181115.html
- 90) Mitsuba N, Kurisu S, Kato Y, Ishibashi K, Fujii Y, Dohi Y, Nishioka K, Kihara Y. Adrenal venous sampling by using gadopentetate dimeglumine in patients with contraindications for iodinated contrast agents. *Int J Cardiol.* 2012 ; 157 (2) : e23-25.
- 91) Yen RF, Wu VC, Liu KL, Cheng MF, Wu YW, Chueh SC, Lin WC, Wu KD, Tzen KY, Lu CC; TAIPAI Study Group. 131I-6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. *J Nucl Med.* 2009 ; 50 (10) : 1631-1637.
- 92) Di Martino M, García Sanz I, Muñoz de Nova JL, Marín Campos C, Martínez Martín M, Domínguez Gadea L. NP-59 test for preoperative localization of primary hyperaldosteronism. *Langenbecks Arch Surg.* 2017 ; 402 (2) : 303-308.
- 93) Nomura K, Kusakabe K, Maki M, Ito Y, Aiba M, Demura H. Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: relationship to adenoma size and functional activity. *J Clin Endocrinol Metab.* 1990 ; 71 (4) : 825-830.
- 94) Xiao L, Jiang Y, Zhang C, Jiang L, Zhou W, Su T, Ning G, Wang W. A novel clinical nomogram to predict bilateral hyperaldosteronism in Chinese patients with primary aldosteronism. *Clin Endocrinol (Oxf).* 2019 ; 90 (6) : 781-788.
- 95) Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, Kurihara I, Umakoshi H, Ichijo T, Katabami T, Wada N, Ogawa Y, Yoshimoto T, Kawashima J, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Miyauchi S, Kamemura K, Fukuoka T, Yamamoto K, Otsuki M, Suzuki T, Naruse M; JPAS Study Group. Obesity as a key factor underlying idiopathic hyperaldosteronism. *J Clin Endocrinol Metab.* 2018 ; 103 (12) : 4456-4464.
- 96) Akasaka H, Yamamoto K, Rakugi H, Nagasawa M, Nakamaru R, Ichijo T, Takeda Y, Kurihara I, Katabami T, Tsuiki M, Wada N, Ogawa Y, Kawashima J, Sone M, Kamemura K, Yoshimoto T, Matsuda Y, Fujita M, Kobayashi H, Watanabe M, Tamura K, Okamura S, Miyauchi S, Izawa S, Chiba Y, Tanabe A, Naruse M; Japan Primary Aldosteronism Study Group. Sex difference in the association between subtype distribution and age at diagnosis in patients with primary aldosteronism. *Hypertension.* 2019 ; 74 (2) : 368-374.
- 97) Vonend O, Ockenfels N, Gao X, Allolio B, Lang K, Mai K, Quack I, Saleh A, Degenhart C, Seufert J, Seiler L, Beuschlein F, Quinkler M, Podrabsky P, Bidlingmaier M, Lorenz R, Reincke M, Rump LC; German Conn's Registry. Adrenal venous sampling: evaluation of the German Conn's Registry. *Hypertension.* 2011 ; 57 (5) : 990-995.
- 98) Jakobsson H, Farmaki K, Sakinis A, Ehn O, Johannsson G, Ragnarsson O. Adrenal venous sampling: the learning curve of a single interventionalist with 282 consecutive procedures. *Diagn Interv Radiol* 2018 ; 24 (2) : 89-93.
- 99) Wolley MJ, Ahmed AH, Gordon RD, Stowasser M. Does ACTH improve the diagnostic performance of adrenal vein sampling for subtyping primary aldosteronism? *Clin Endocrinol (Oxf)* 2016 ; 85 (5) : 703-709.
- 100) Takeda Y, Umakoshi H, Takeda Y, Yoneda T, Kurihara I, Katabami T, Ichijo T, Wada N, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Yanase T, Suzuki T, Naruse M; JPAS Study Group. Impact of adrenocorticotropic hormone stimulation during adrenal venous sampling on outcomes of primary aldosteronism. *J Hypertens.* 2019 ; 37 (5) : 1077-1082.
- 101) Onozawa S, Murata S, Tajima H, Yamaguchi H, Mine T, Ishizaki A, Sugihara H, Oikawa S, Kumita S. Evaluation of right adrenal vein cannulation by computed tomography angiography in 140 consecutive patients undergoing adrenal venous sampling. *Eur J of Endocrinol.* 2014 ; 170 (4) : 601-608.
- 102) Chang CC, Lee BC, Chang YC, Wu VC, Huang KH, Liu KL; TAIPAI Study Group. Comparison of C-arm computed tomography and on-site quick cortisol assay for adrenal venous sampling: a retrospective study of 178 patients. *Eur Radiol.* 2017 ; 27 (12) : 5006-5014.
- 103) Omura K, Ota H, Takahashi Y, Matsuura T, Seiji K, Arai Y, Morimoto R, Satoh F, Takase K. Anatomical variations of the right adrenal vein concordance between multidetector computed tomography and catheter venography. *Hypertension.* 2017 ; 69 (3) : 428-434.

- 104) Onozawa S, Murata S, Yamaguchi H, Mine T, Yasui D, Sugihara H, Tajima H. Can an enhanced thin-slice computed tomography delineate the right adrenal vein and improve the success rate? *Jpn J of Radiol.* 2016 ; 34 (9) : 611-619.
- 105) Araki T, Okada H, Onishi H. Does catheter shape influence the success of right adrenal venous sampling? the interaction of catheter shape to anatomical factors on CT. *Jpn J of Radiol.* 2016 ; 34 (11) : 707-717.
- 106) Chang CC, Lee BC, Liu KL, Chang YC, Wu VC, Huang KH. Non-stimulated adrenal venous sampling using Dyna computed tomography in patients with primary aldosteronism. *Sci Rep.* 2016 ; 6 : 37143.
- 107) Yoneda T, Karashima S, Kometani M, Usukura M, Demura M, Sanada J, Minami T, Koda W, Gabata T, Matsui O, Idegami K, Takamura Y, Tamiya E, Oe M, Nakai M, Mori S, Terayama N, Matsuda Y, Kamemura K, Fujii S, Seta T, Sawamura T, Okuda R, Takeda Y, Hayashi K, Yamagishi M, Takeda Y. Impact of new quick gold nanoparticle-based cortisol assay during adrenal vein sampling for primary aldosteronism. *J Clin Endocrinol Metab.* 2016 ; 101 (6) : 2554-2561.
- 108) Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, Degenhart C, Deinum J, Fischer E, Gordon R, Kickuth R, Kline G, Lacroix A, Magill S, Miotto D, Naruse M, Nishikawa T, Omura M, Pimenta E, Plouin PF, Quinkler M, Reincke M, Rossi E, Rump LC, Satoh F, Schultze Kool L, Seccia TM, Stowasser M, Tanabe A, Trerotola S, Vonend O, Widimsky J Jr, Wu KD, Wu VC, Pessina AC. The adrenal vein sampling international study (AVIS) for identifying the major subtypes of primary aldosteronism. *J Clin Endocrinol Metab.* 2012 ; 97 (5) : 1606-1614.
- 109) Kobayashi H, Nakamura Y, Abe M, Kurihara I, Itoh H, Ichijo T, Takeda Y, Yoneda T, Katabami T, Tsuiki M, Wada N, Ogawa Y, Sakamoto R, Kawashima J, Sone M, Inagaki N, Yoshimoto T, Yamada T, Okamoto R, Matsuda Y, Fujita M, Watanabe M, Tamura K, Tanabe A, Naruse M; JPAS/JRAS Study Group. Effect of cosyntropin during adrenal venous sampling on subtype of primary aldosteronism: analysis of surgical outcome. *Eur J Endocrinol.* 2020 ; 182 (3) : 265-273.
- 110) Satoh F, Abe T, Tanemoto M, Nakamura M, Abe M, Uruno A, Morimoto R, Sato A, Takase K, Ishidoya S, Arai Y, Suzuki T, Sasano H, Ishibashi T, Ito S. Localization of aldosterone-producing adrenocortical adenomas: significance of adrenal venous sampling. *Hypertens Res.* 2007 ; 30 (11) : 1083-1095.
- 111) Phillips JL, Walther MM, Pezzullo JC, Rayford W, Choyk PL, Berman AA, Linehan WM, Doppman JL, Gill JR Jr. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. *J Clin Endocrinol Metab.* 2000 ; 85 (12) : 4526-4533.
- 112) Seccia TM, Miotto D, De Toni R, Pitter G, Mantero F, Pessina AC, Rossi GP. Adrenocorticotrophic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. *Hypertension.* 2009 ; 53 (3) : 761-766.
- 113) Tanemoto M, Suzuki T, Abe M, Abe T, Ito S. Physiologic variance of corticotropin affects diagnosis in adrenal vein sampling. *Eur J Endocrinol.* 2009 ; 160 (3) : 459-463.
- 114) Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. *Surgery.* 2004 ; 136 (6) : 1227-1235.
- 115) Ceral J, Solar M, Krajina A, Ballon M, Suba P, Cap J. Adrenal venous sampling in primary aldosteronism: a low dilution of adrenal venous blood is crucial for a correct interpretation of the results. *Eur J Endocrinol.* 2010 ; 162 (1) : 101-107.
- 116) Rossitto G, Amar L, Azizi M, Riestler A, Reincke M, Degenhart C, Widimsky J, Naruse M, Deinum J, Schultzekool L, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Rump LC, Vonend O, Willenberg HS, Fuller P, Yang J, Nian Chee NY, Magill SB, Shafiqullina Z, Quinkler M, Oliveras A, Chang CC, Wu VC, Somloova Z, Maiolino G, Barbiero G, Battistel M, Lenzi L, Quaia E, Pessina AC, Rossi GP. Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization. *J Clin Endocrinol Metab.* 2020 ; 105 (6) : dgz017.
- 117) Shibayama Y, Wada N, Naruse M, Kurihara I, Ito H, Yoneda T, Takeda Y, Umakoshi H, Tsuiki M, Ichijo T, Fukuda H, Katabami T, Yoshimoto T, Ogawa Y, Kawashima J, Ohno Y, Sone M, Fujita M, Takahashi K, Shibata H, Kamemura K, Fujii Y, Yamamoto K, Suzuki T. The occurrence of apparent bilateral aldosterone suppression in adrenal vein sampling for primary aldosteronism. *J Endocr Soc.* 2018 ; 2 (5) : 398-407.
- 118) Strajina V, Al-Hilli Z, Andrews JC, Bancos I, Thompson GB, Farley DR, Lyden ML, Dy BM, Young WF, McKenzie TJ. Primary aldosteronism: making sense of partial data sets from failed adrenal venous sampling-suppression of adrenal aldosterone production can be used in clinical decision making. *Surgery.* 2018 ; 163 (4) : 801-806.
- 119) Wang TS, Kline G, Yen TW, Yin Z, Liu Y, Rilling W, So B, Findling JW, Evans DB, Pasieka JL. A multi-institutional comparison of adrenal venous sampling in patients with primary aldosteronism: caution advised if successful bilateral adrenal vein sampling is not achieved. *World J Surg.* 2018 ; 42 (2) : 466-472.
- 120) Fujii Y, Umakoshi H, Wada N, Ichijo T, Kamemura K, Matsuda Y, Kai T, Fukuoka T, Sakamoto R, Ogo A, Suzuki T, Nanba K, Tsuiki M, Naruse M; WAVES-J Study Group. Subtype prediction of primary aldosteronism by combining aldosterone concentrations in the left adrenal vein and inferior vena cava: a multicenter collaborative study on adrenal venous sampling. *J Human Hypertens.* 2018 ; 32 (1) : 12-19.
- 121) Goupil R, Wolley M, Ahmed AH, Gordon RD, Stowasser M. Does concomitant autonomous adrenal cortisol overproduction have the potential to confound the interpretation of adrenal venous sampling in primary aldosteronism? *Clin Endocrinol (Oxf).* 2015 ; 83 (4) : 456-461.
- 122) Kishino M, Yoshimoto T, Nakadate M, Katada Y, Kanda E, Nakaminato S, Saida Y, Ogawa Y, Tateishi U. Optimization of left adrenal vein sampling in primary aldosteronism: coping with asymmetrical cortisol secretion. *Endocr J.* 2017 ; 64 (3) : 347-355.
- 123) Takeda M, Yamamoto K, Akasaka H, Rakugi H, Naruse M, Takeda Y, Kurihara I, Itoh I, Umakoshi H, Tsuiki M, Ichijo I, Katabami T, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Ogo A, Okamura S, Miyauchi S, Yanase T, Suzuki T,

- Kawamura T, JPAS Study Group. Clinical characteristics and postoperative outcomes of primary aldosteronism in the elderly. *J Clin Endocrinol Metab.* 2018; 103 (10) : 3620-3629.
- 124) Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Beuschlein F, Satoh F, Morimoto R, Amar L, Quinkler M, Deinum J, Kitamoto K, Nishikawa T, Pham U, Stowasser M, Umakoshi H, Naruse M, Prejbisz A, Kocjan T, Young WF Jr, Gomez-Sanchez CE, Funder JW, Reincke M. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. *Lancet Diabetes Endocrinol* 2017 ; 5 (9) : 689-699.
- 125) Umakoshi H, Tsuiji M, Yokomoto-Umakoshi M, Takeda Y, Takashi Y, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ashida K, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Okamura S, Miyauchi S, Fukuoka T, Izawa S, Yanase T, Hashimoto S, Yamada M, Yoshikawa Y, Kai T, Suzuki T, Kawamura T, Naruse M. Correlation between lateralization index of adrenal venous sampling and standardized outcome in primary aldosteronism. *J Endocr Soc.* 2018 ; 2 (8) : 893-902.
- 126) Umakoshi H, Naruse M, Wada N, Ichijo T, Kamemura K, Matsuda Y, Fujii Y, Kai T, Fukuoka T, Sakamoto R, Ogo A, Suzuki T, Nanba K, Tsuiji M; WAVES-J Study Group. Adrenal venous sampling in patients with positive screening but negative confirmatory testing for primary aldosteronism. *Hypertension.* 2016 ; 67 (5) : 1014-1019.
- 127) Benham JL, Eldoma M, Khokhar B, Roberts DJ, Rabi DM, Kline GA. Proportion of patients with hypertension resolution following adrenalectomy for primary aldosteronism: a systematic review and meta-analysis. *J Clin Hypertens (Greenwich).* 2016 ; 18 (12) : 1205-1212.
- 128) Nakamaru R, Yamamoto K, Rakugi H, Akasaka H, Kurihara I, Ichijo T, Takeda Y, Katabami T, Tsuiji M, Wada N, Ogawa Y, Kawashima J, Sone M, Yoshimoto T, Okamoto R, Fujita M, Kobayashi H, Tamura K, Kamemura K, Okamura S, Kakutani M, Tanabe A, Naruse M; JPAS/JRAS Study Group. Obesity predicts persistence of resistant hypertension after surgery in patients with primary aldosteronism. *Clin Endocrinol (Oxf).* 2020 ; 93 (3) : 229-237.
- 129) Satoh M, Maruhashi T, Yoshida Y, Shibata H. Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism. *Hypertens Res.* 2019 ; 42 (6) : 817-824.
- 130) Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. *JAMA Cardiol.* 2018 ; 3 (8) : 768-774.
- 131) Hundemer GL, Gary C Curhan GC, Yozamp N, Wang M, Vaidya A. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism. *Hypertension.* 2018 ; 72 (3) : 658-666.
- 132) Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. *Lancet Diabetes Endocrinol.* 2018 ; 6 (1) : 51-59.
- 133) Kobayashi Y, Haze T, Yano Y, Tamura K, Kurihara I, Ichijo T, Yoneda T, Katabami T, Tsuiji M, Wada N, Ogawa Y, Kawashima J, Sone M, Inagaki N, Yamada T, Okamoto R, Fujita M, Kamemura K, Yamamoto K, Izawa S, Tanabe A, Naruse M; JPAS/JRAS Study Group. Associations Between Changes in Plasma Renin Activity and Aldosterone Concentrations and Changes in Kidney Function After Treatment for Primary Aldosteronism. *Kidney Int Rep.* 2020 ; 5 (8) : 1291-1297.
- 134) Kyo S, Imanaka K, Masuda M, Miyata T, Morita K, Morota T, Nomura M, Saiki Y, Sawa Y, Sueda T, Ueda Y, Yamazaki K, Yozu R, Iwamoto M, Kawamoto S, Koyama I, Kudo M, Matsumiya G, Orihashi K, Oshima H, Saito S, Sakamoto Y, Shigematsu K, Taketani T, Komuro I, Takamoto S, Tei C, Yamamoto F, on behalf of the Japanese Circulation Society Joint Working Group. Guidelines for perioperative cardiovascular evaluation and management for noncardiac surgery (JCS 2014). *Digest Version Circ J.* 2017 ; 81 (2) : 245-67.
- 135) Wada N, Shibayama Y, Umakoshi H, Ichijo T, Fujii Y, Kamemura K, Kai T, Sakamoto R, Ogo A, Matsuda Y, Fukuoka T, Tsuiji M, Suzuki T, Naruse M. Hyperkalemia in both surgically and medically treated patients with primary aldosteronism. *J Hum Hypertens.* 2017 ; 31 (10) : 627-632.
- 136) Park KS, Kim JH, Ku EJ, Hong AR, Moon MK, Choi SH, Shin CS, Kim SW, Kim SY. Clinical risk factors of postoperative hyperkalemia after adrenalectomy in patients with aldosterone-producing adenoma. *Eur J Endocrinol.* 2015 ; 172 (6) : 725-731.
- 137) Yanase T, Tajima T, Katabami T, Iwasaki Y, Tanahashi Y, Sugawara A, Hasegawa T, Mune T, Oki Y, Nakagawa Y, Miyamura N, Shimizu C, Otsuki M, Nomura M, Akehi Y, Tanabe M, Kasayama S. Diagnosis and treatment of adrenal insufficiency including adrenal crisis: a Japan Endocrine Society clinical practice guideline. *Endocr J* 2016 ; 63 (9) : 765-784.
- 138) Colussi G, Catena C, Sechi LA. Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. *J Hypertens.* 2013 ; 31 (1) : 3-15.
- 139) Parthasarathy HK, Ménard J, White WB, Young WF Jr, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM, MacDonald TM. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. *J Hypertens.* 2011 ; 29 (5) : 980-990.
- 140) Fourkiotis V, Vonend O, Diederich S, Fischer E, Lang K, Endres S, Beuschlein F, Willenberg HS, Rump LC, Allolio B, Reincke M, Quinkler M; Mephisto Study Group. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. *Eur J Endocrinol.* 2013 ; 168 (1) : 75-81.
- 141) Karashima S, Yoneda T, Kometani M, Ohe M, Mori S, Sawamura T, Furukawa K, Seta T, Yamagishi M, Takeda Y. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. *Hypertens Res.* 2016 ; 39 (3) : 133-137.
- 142) Nakamaru R, Yamamoto K, Akasaka H, Rakugi H, Kurihara I, Yoneda T, Ichijo T, Katabami T, Tsuiji M, Wada N, Yamada T, Kobayashi H, Tamura K, Ogawa Y, Kawashima J, Inagaki N, Fujita M, Oki K, Kamemura K, Tanabe A, Naruse M; JPAS/JRAS study group. Sex Differences in Renal Outcomes after Medical Treatment for Bilateral Primary Aldosteronism. *Hypertension.* 2021 ; 77 (2) : 537-545.

- 143) Murata M, Kitamura T, Tamada D, Mukai K, Kurebayashi S, Yamamoto T, Hashimoto K, Hayashi RD, Kouhara H, Takeiri S, Kajimoto Y, Nakao M, Hamasaki T, Otsuki M, Shimomura I. Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. *J Hypertens*. 2017 ; 35 (5) : 1079-1085.
- 144) Cesari M, Letizia C, Angeli P, Sciomer S, Rosi S, Rossi GP. cardiac remodeling in patients with primary and secondary aldosteronism: A tissue doppler study. *Circ Cardiovasc Imaging*. 2016 ; 9 (6) : e004815.
- 145) Catena C, Colussi GL, Marzano L, Sechi LA. Predictive factors of left ventricular mass changes after treatment of primary aldosteronism. *Horm Metab Res*. 2012 ; 44 (3) : 188-193.
- 146) Ito Y, Takeda R, Karashima S, Yamamoto Y, Yoneda T, Takeda Y. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. *Hypertens Res*. 2011 ; 34 (1) : 98-102
- 147) Baudrand R, Guarda FJ, Fardella C, Hundemer G, Brown J, Williams G, Vaidya A. Continuum of Renin-Independent Aldosteronism in Normotension. *Hypertension*. 2017 ; 69 (5) : 950-956.
- 148) Brown JM, Robinson-Cohen C, Luque-Fernandez MA, Allison MA, Baudrand R, Ix JH, Kestenbaum B, de Boer IH, Vaidya A. The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study. *Ann Intern Med*. 2017 ; 167 (9) : 630-641.
- 149) 日本妊娠高血圧学会編集. 妊娠高血圧症候群の診療指針 2015 : Best Practice Guide. メジカルビュー社. 2015.
- 150) 日本産科婦人科学会, 日本産婦人科医会編集, 産婦人科診療ガイドライン産科編 2017. 2017.
- 151) Landau E, Amar L. Primary aldosteronism and pregnancy. *Ann Endocrinol (Paris)*. 2016 ; 77 (2) : 148-160.
- 152) Morton A. Primary aldosteronism and pregnancy. *Pregnancy Hypertens*. 2015 ; 5 (4) : 259-262.
- 153) Riestler A, Reincke M. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy. *Eur J Endocrinol*. 2015 ; 172 (1) : R23-30.
- 154) Jansen PM, van den Born BJ, Frenkel WJ, de Bruijne EL, Deinum J, Kerstens MN, Smulders YM, Woittiez AJ, Wijbenga JA, Zietse R, Danser AH, van den Meiracker AH. Test characteristics of the aldosterone-to-renin ratio as a screening test for primary aldosteronism. *J Hypertens*. 2014 ; 32 (1) : 115-126.
- 155) Ma L, Song Y, Mei M, He W, Hu J, Cheng Q, Tang Z, Luo T, Wang Y, Zhen Q, Wang Z, Qing H, He Y, Li Q, Yang S; the Chongqing Primary Aldosteronism Study (COMPASS) Group. Age-related cutoffs of plasma aldosterone/renin concentration for primary aldosteronism screening. *Int J Endocrinol*. 2018 Jul 16 ; 2018 : 8647026. (オンライン : doi: 10.1155/2018/8647026)
- 156) Nakama C, Kamide K, Kawai T, Hongyo K, Ito N, Onishi M, Takeya Y, Yamamoto K, Sugimoto K, Rakugi H. The influence of aging on the diagnosis of primary aldosteronism. *Hypertens Res*. 2014 ; 37 (12) : 1062-1067.
- 157) Cornu E, Steichen O, Nogueira-Silva L, Kupers E, Pagny JY, Grataloup C, Baron S, Zinzindohoue F, Plouin PF, Amar L. Suppression of aldosterone secretion after recumbent saline infusion does not exclude lateralized primary aldosteronism. *Hypertension*. 2016 ; 68 (4) : 989-994.
- 158) Meng X, Li Y, Wang X, Li J, Liu Y, Yu Y. Evaluation of the saline infusion test and the captopril challenge test in chinese patients with primary aldosteronism. *J Clin Endocrinol Metab*. 2018 ; 103 (3) : 853-860.
- 159) Nakamaru R, Yamamoto K, Akasaka H, Rakugi H, Kurihara I, Yoneda T, Ichijo T, Katabami T, Tsuiki M, Wada N, Yamada T, Kobayashi H, Tamura K, Ogawa Y, Kawashima J, Inagaki N, Fujita M, Watanabe M, Kamemura K, Okamura S, Tanabe A, Naruse M; JPAS/JRAS Study Group. Age-stratified comparison of clinical outcomes between medical and surgical treatments in patients with unilateral primary aldosteronism. *Sci Rep*. 2021 ; 11 (1) : 6925.
- 160) Meng X, Ma WJ, Jiang XJ, Lu PP, Zhang Y, Fan P, Cai J, Zhang HM, Song L, Wu HY, Zhou XL, Lou Y. Long-term blood pressure outcomes of patients with adrenal venous sampling-proven unilateral primary aldosteronism. *J Hum Hypertens*. 2020 ; 34 (6) : 440-447.
- 161) Puar TH, Loh LM, Loh WJ, Lim DST, Zhang M, Tan PT, Lee L, Swee DS, Khoo J, Tay D, Tan SY, Zhu L, Gani L, King TF, Kek PC, Foo RS. Outcomes in unilateral primary aldosteronism after surgical or medical therapy. *Clin Endocrinol (Oxf)*. 2021 ; 94 (2) : 158-167.
- 162) Wu VC, Wang SM, Chang CH, Hu YH, Lin LY, Lin YH, Chueh SC, Chen L, Wu KD. Long term outcome of Aldosteronism after target treatments. *Sci Rep*. 2016 ; 6 : 32103.
- 163) Wu VC, Chueh SJ, Chen L, Chang CH, Hu YH, Lin YH, Wu KD, Yang WS; TAIPAI Study Group. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. *J Hypertens*. 2017 ; 35 (8) : 1698-1708.
- 164) Mulatero P, Sechi LA, Williams TA, Lenders JWM, Reincke M, Satoh F, Januszewicz A, Naruse M, Doumas M, Veglio F, Wu VC, Widimsky J. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. *J Hypertens*. 2020 ; 38 (10) : 1929-1936.
- 165) Zhou Y, Zhang M, Ke S, Liu L. Hypertension outcomes of adrenalectomy in patients with primary aldosteronism: a systematic review and meta-analysis. *BMC Endocr Disord*. 2017 ; 17 (1) : 61.
- 166) Morisaki M, Kurihara I, Itoh H, Naruse M, Takeda Y, Katabami T, Ichijo T, Wada N, Yoshimoto T, Ogawa Y, Sone M, Tsuiki M, Shibata H, Kawashima J, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Suzuki T; JPAS Study Group. Predictors of clinical success after surgery for primary aldosteronism in the Japanese nationwide cohort. *J Endocr Soc*. 2019 ; 3 (11) : 2012-2022.
- 167) Kitamoto T, Omura M, Suematsu S, Saito J, Nishikawa T. KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of aldosterone-producing adenoma. *J Hypertens*. 2018 ; 36 (3) : 619-627.
- 168) Utsumi T, Kamiya N, Kaga M, Endo T, Yano M, Kamijima S, Kawamura K, Imamoto T, Ichikawa T, Suzuki H. Development of novel nomograms to predict renal functional outcomes after laparoscopic adrenalectomy in patients with primary aldosteronism. *World J Urol*. 2017 ; 35 (10) : 1577-1583.

- 169) Shariq OA, Bancos I, Cronin PA, Farley DR, Richards ML, Thompson GB, Young WF Jr, McKenzie TJ. Contralateral suppression of aldosterone at adrenal venous sampling predicts hyperkalemia following adrenalectomy for primary aldosteronism. *Surgery*. 2018 ; 163 (1) : 183-190.
- 170) Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Åkerström G, Wang W, Carling T, Lifton RP. K⁺ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. *Science*. 2011 ; 331 (6018) : 768-772.
- 171) Murakami M, Yoshimoto T, Nakabayashi K, Nakano Y, Fukaiishi T, Tsuchiya K, Minami I, Bouchi R, Okamura K, Fujii Y, Hashimoto K, Hata KI, Kihara K, Ogawa Y. Molecular characteristics of the KCNJ5 mutated aldosterone-producing adenomas. *Endocr Relat Cancer*. 2017 ; 24 (10) : 531-541.
- 172) Nakano Y, Yoshimoto T, Watanabe R, Murakami M, Fukuda T, Saito K, Fujii Y, Akashi T, Tanaka T, Yamada T, Naruse M, Ogawa Y. miRNA299 involvement in CYP11B2 expression in aldosterone-producing adenoma. *Eur J Endocrinol*. 2019 ; 181 (1) : 69-78.
- 173) Vilela LAP, Rassi-Cruz M, Guimaraes AG, Moises CCS, Freitas TC, Alencar NP, Petenuci J, Goldbaum TS, Maciel AAW, Pereira MAA, Silva GV, Pio-Abreu A, Zerbini MCN, Cavalcante ACBS, Carnevale FC, Pilan B, Yamauchi F, Srougi V, Tanno FY, Chambo JL, Latronico AC, Mendonca BB, Fragoso MCBV, Bortolotto LA, Drager LF, Almeida MQ. KCNJ5 somatic mutation is a predictor of hypertension remission after adrenalectomy for unilateral primary aldosteronism. *J Clin Endocrinol Metab*. 2019 ; 104 (10) : 4695-4702.
- 174) Juutilainen A, Savolainen K, Romppanen J, Turpeinen U, Hämäläinen E, Kempainen J, Moilanen L, Pulkki K, Juutilainen A, Savolainen K, Romppanen J, Turpeinen U, Hämäläinen E, Kempainen J, Moilanen L, Pulkki K. Combination of LC-MS/MS aldosterone and automated direct renin in screening for primary aldosteronism. *Clin Chim Acta*. 2014 ; 433 : 209-215.
- 175) Satoh F, Morimoto R, Ono Y, Iwakura Y, Omata K, Kudo M, Takase K, Seiji K, Sasamoto H, Honma S, Okuyama M, Yamashita K, Gomez-Sanchez CE, Rainey WE, Arai Y, Sasano H, Nakamura Y, Ito S. Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism. *Hypertension*. 2015 ; 65 (5) : 1096-1102.
- 176) Tezuka Y, Yamazaki Y, Kitada M, Morimoto R, Kudo M, Seiji K, Takase K, Kawasaki Y, Mitsuzuka K, Ito A, Nishikawa J, Asai N, Nakamura Y, Gomez-Sanchez CE, Ito S, Dezawa M, Sasano H, Satoh F. 18-Oxocortisol synthesis in aldosterone-producing adrenocortical adenoma and significance of KCNJ5 mutation status. *Hypertension*. 2019 ; 73 (9) : 1283-1290.
- 177) Soinio M, Luukkonen AK, Seppänen M, Kempainen J, Seppänen J, Pienimäki JP, Leijon H, Vesterinen T, Arola J, Lantto E, Helin S, Tikkanen I, Metso S, Mirtti T, Heiskanen I, Norvio L, Tiikkainen M, Tikkanen T, Sane T, Välimäki M, Gomez-Sanchez CE, Pörsti I, Nuutila P, Nevalainen PI, Matikainen N. Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism. *Eur J Endocrinol*. 2020 ; 183 (6) : 539-550.
- 178) Ding J, Zhang Y, Wen J, Zhang H, Wang H, Luo Y, Pan Q, Zhu W, Wang X, Yao S, Kreissl MC, Hacker M, Tong A, Huo L, Li X. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. *Eur J Nucl Med Mol Imaging*. 2020 ; 47 (11) : 2656-2665.
- 179) Abe T, Naruse M, Young WF Jr, Kobashi N, Doi Y, Izawa A, Akama K, Okumura Y, Ikenaga M, Kimura H, Saji H, Mukai K, Matsumoto H. A novel CYP11B2-specific imaging agent for detection of unilateral subtypes of primary aldosteronism. *J Clin Endocrinol Metab* 2016 ; 101 (3) : 1008-1015.
- 180) Satoh F, Morimoto R, Seiji K, Satani N, Ota H, Iwakura Y, Ono Y, Kudo M, Nezu M, Omata K, Tezuka Y, Kawasaki Y, Ishidoya S, Arai Y, Takase K, Nakamura Y, McNamara K, Sasano H, Ito S. Is there a role for segmental adrenal venous sampling and adrenal sparing surgery in patients with primary aldosteronism? *Eur J Endocrinol*. 2015 ; 173 (4) : 465-477.
- 181) Williams TA, Gomez-Sanchez CE, Rainey WE, Giordano TJ, Lam AK, Marker A, Mete O, Yamazaki Y, Zerbini MCN, Beuschlein F, Satoh F, Burrello J, Schneider H, Lenders JWM, Mulatero P, Castellano I, Knösel T, Papotti M, Saeger W, Sasano H, Reincke M. International histopathology consensus for unilateral primary aldosteronism. *J Clin Endocrinol Metab*. 2021 ; 106 (1) : 42-54.
- 182) Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. *Am J Hypertens*. 2012 ; 25 (5) : 514-522
- 183) Anceschi U, Tuderti G, Fiori C, Zappalà O, Ferriero MC, Brassetti A, Carrara A, Tirone G, De Concilio B, Celia A, Porpiglia F, Simone G. Minimally Invasive Partial Versus Total Adrenalectomy for the Treatment of Primary Aldosteronism: Results of a Multicenter Series According to the PASO Criteria. *Eur Urol Focus*. 2020 ; S2405-4569 (20) 30189-9.
- 184) Simone G, Anceschi U, Tuderti G, Misuraca L, Celia A, De Concilio B, Costantini M, Stigliano A, Minisola F, Ferriero M, Guaglianone S, Gallucci M. Robot-assisted partial adrenalectomy for the treatment of conn's syndrome: surgical technique, and perioperative and functional outcomes. *Eur Urol*. 2019 ; 75 (5) : 811-816.
- 185) Bouhanick B, Delchier MC, Lagarde S, Boulestreau R, Conil C, Gosse P, Rousseau H, Lepage B, Olivier P, Papadopoulos P, Trillaud H, Cremer A; ADERADHTA group. Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study. *J Hypertens*. 2021 ; 39 (4) : 759-765
- 186) Zhang H, Li Q, Liu X, Zhao Z, He H, Sun F, Hong Y, Zhou X, Li Y, Shen R, Bu X, Yan Z, Zheng H, Yang G, Zhu Z; Chongqing Endocrine Hypertension Collaborative Team. Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: an efficacy and safety, proof-of-principle trial. *J Clin Hypertens (Greenwich)*. 2020 ; 22 (9) : 1618-1626.